Skip to main content

ACROMICS: medicina de precisión de futuro en el diagnóstico y tratamiento de la Acromegalia

PMP22/00021

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Afrontar las Prioridades de Nuestro Entorno
Call Proyectos de Investigación de Medicina Personalizada de Precisión
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Personalized Medicine in Acromegaly, The ACROFAST Study, Medicina Personalizada en Acromegalia

  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Sampedro Núñez, Miguel Antonio
  • Valassi, Elena|||0000-0002-3864-0105
  • Biagetti, Betina|||0000-0002-8837-4343
  • Giménez-Palop, Olga|||0000-0002-4526-6342
  • Hernández García, Marta|||0000-0003-1237-298X
  • Martínez, Silvia
  • Carrato, Cristina|||0000-0002-1953-8287
  • Villar Taibo, Rocío
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Blanco Carrera, Concepción|||0000-0001-7171-9459
  • Simón-Muela, Inmaculada
  • Simó-Servat, Andreu|||0000-0002-1092-1327
  • Xifra, Gemma
  • Vázquez, Federico|||0000-0001-6493-2374
  • Pavón, Isabel
  • Rosado, José Antonio
  • García Centeno, Rogelio
  • Zavala, Roxana
  • Hanzu, Felicia A.|||0000-0002-2399-4023
  • Mora, Mireia|||0000-0002-5887-5016
  • Aulinas, Anna|||0000-0002-1205-7114
  • Vilarrasa, Nuria|||0000-0003-3188-1990
  • Librizzi, Soledad
  • Calatayud, María|||0000-0002-6737-7289
  • de Miguel, Paz
  • Álvarez-Escolá, Cristina|||0000-0002-4684-1652
  • Picó Alfonso, Antonio M.|||0000-0002-7549-7563
  • Salinas, Isabel
  • Fajardo-Montañana, Carmen|||0000-0002-0784-0761
  • Cámara, Rosa|||0000-0002-3289-3400
  • Bernabeu Morón, Ignacio|||0000-0001-8421-7394
  • Jordà, Mireia|||0000-0003-3709-1850
  • Webb, S. M.|||0000-0001-7052-6436
  • Marazuela, Mónica|||0000-0003-1158-9618
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Context: Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. Some biomarkers can predict fgSRLs response. Objective:Here we report the results of the ACROFAST study, a clinical trial in which a protocol based on predictive biomarkers of fgSRLs was evaluated. Methods: This was a prospective trial (21 university hospitals) comparing the effectiveness and time-to-control of 2 treatment protocols during 12 months: (A) a personalized protocol in which the first options were fgSRLs as monotherapy or in combination with pegvisomant, or pegvisomant as monotherapy depending on the short acute octreotide test (sAOT) results, tumor T2 magnetic resonance (MRI) signal or immunostaining for E-cadherin; and (B) a control group with treatment always started by fgSRLs and the other drugs included after demonstrating inadequate control. Results:Eighty-five patients participated; 45 in the personalized and 40 in the control group. More patients in the personalized protocol achieved hormonal control compared to those in the control group (78% vs 53%, P < .05). Survival analysis revealed a hazard ratio for achieving hormonal control adjusted by age and sex of 2.53 (CI, 1.30-4.80). Patients from the personalized arm were controlled in a shorter period of time (P = .01). Conclusion:Personalized medicine is feasible using a relatively simple protocol, and it allows a higher number of patients to achieve control in a shorter period of time.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Primary Cilia as a Tumor Marker in Pituitary Neuroendocrine Tumors

  • Martínez-Hernández, Rebeca
  • Serrano-Somavilla, Ana
  • Fernández-Contreras, Raul
  • Sanchez-Guerrero, Cristina
  • Sánchez de la Blanca, Nuria
  • Sacristán-Gómez, Pedro
  • Sebastian-Valles, Fernando|||0000-0002-4127-0483
  • Sampedro Núñez, Miguel Antonio
  • Fraga, Javier
  • Calatayud, María|||0000-0002-6737-7289
  • Vicente, Almudena
  • García-de-Casasola, G.|||0000-0002-5171-7373
  • Sanz-García, Ancor
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Ruz-Caracuel, Ignacio|||0000-0002-2298-4683
  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Marazuela, Mónica|||0000-0003-1158-9618
Pituitary neuroendocrine tumors (PitNETs) account for approximately 15% of all intracranial neoplasms. Although they usually appear to be benign, some tumors display worse behavior, displaying rapid growth, invasion, refractoriness to treatment, and recurrence. Increasing evidence supports the role of primary cilia (PC) in regulating cancer development. Here, we showed that PC are significantly increased in PitNETs and are associated with increased tumor invasion and recurrence. Serial electron micrographs of PITNETs demonstrated different ciliation phenotypes (dot-like versus normal-like cilia) that represented PC at different stages of ciliogenesis. Molecular findings demonstrated that 123 ciliary-associated genes (eg, doublecortin domain containing protein 2, Sintaxin-3, and centriolar coiled-coil protein 110) were dysregulated in PitNETs, representing the upregulation of markers at different stages of intracellular ciliogenesis. Our results demonstrate, for the first time, that ciliogenesis is increased in PitNETs, suggesting that this process might be used as a potential target for therapy in the future.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acromegaly facial changes analysis using last generation artificial intelligence methodology, the AcroFace system

  • Rashwan, Hatem A.
  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Ruiz, Sabina
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Asensio-Wandosell, Diego|||0009-0005-6439-8518
  • Martínez Momblán, Ma. Antonia|||0000-0002-5364-5270
  • Vázquez, Federico|||0000-0001-6493-2374
  • Salinas, Isabel
  • Ciriza, Raquel
  • Jordà, Mireia|||0000-0003-3709-1850
  • Chanson, Philippe|||0000-0001-5096-5722
  • Valassi, Elena|||0000-0002-3864-0105
  • Abdelnasser, Mohamed
  • Puig, Domènec
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Purpose: To describe the development of the AcroFace system, an AI-based system for early detection of acromegaly, based on facial photographs analysis. Methods: Two types of features were explored: (1) the visual/texture of a set of 2D facial images, and (2) geometric information obtained from a reconstructed 3D model from a single image. We optimized acromegaly detection by integrating SVM for geometric features and CNNs for visual features, each chosen for their strength in processing distinct data types effectively. This combination enhances overall accuracy by leveraging SVM's capability to manage structured, quantitative data and CNNs' proficiency in interpreting complex image textures, thus providing a comprehensive analysis of both geometric alignment and textural anomalies. ResNet-50, VGG-16, MobileNet, Inception V3, DensNet121 and Xception models were trained with an expert endocrinologist-based score as a ground truth. Results: ResNet-50 model as a feature extractor and Support Vector Regression (SVR) with a linear kernel showed the best performance (accuracy δ1 of 75% and δ3 of 89%), followed by the VGG-16 as a feature extractor and SVR with a linear kernel. Geometric features yield less accurate results than visual ones. The validation cohort showed the following performance: precision 0.90, accuracy 0.93, F1-Score 0.92, sensitivity 0.93 and specificity 0.93. Conclusion: AcroFace system shows a good performance to discriminate acromegaly and non-acromegaly facial traits that may serve for the detection of acromegaly at an early stage as a screening procedure at a population level.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Quality of life and psychological status in people with acromegaly in relation to disease-related facial changes

  • Martínez Momblán, Ma. Antonia|||0000-0002-5364-5270
  • Alonso Fernández, Sergio|||0000-0001-6969-9380
  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Salinas, Isabel
  • Vázquez, Federico|||0000-0001-6493-2374
  • Soldevila i Madorell, Berta|||0000-0002-4582-4201
  • Asensio-Wandosell, Diego|||0009-0005-6439-8518
  • Ciriza, Raquel
  • Santos, Alicia|||0000-0002-2179-6189
  • Valassi, Elena|||0000-0002-3864-0105
  • Webb, S. M.|||0000-0001-7052-6436
  • Puig Domingo, Manuel|||0000-0002-6744-7195
The diagnosis of acromegaly is often delayed, leading to facial disfigurements that persist despite endocrine cure. We aimed to study the relationship between facial modifications, quality of life (QoL) and psychological status in patients with acromegaly. Methods: Sixty-five patients in remission or with hormonal disease control participated (29 women and 36 men; mean age 57.4 ± 13.5 years). The following variables were assessed: i) sex; ii) QoL by AcroQoL; iii) anxiety level with the STAI questionnaire; iv) self-esteem by the Rosenberg scale; and v) facial acromegaly phenotypical changes evaluated from face photographs by eight experienced endocrinologists using a Likert scale. Results: The global AcroQoL score for the whole cohort showed mid-range values, with higher median values for men (72.3 vs 56.6, P = 0.022) mostly dependent on the physical domain, which was higher for men (59.0 vs 34.9, P = 0.006), rather than the psychological domain (65.7 vs 54.5, P = 0.069). Anxiety scores were also higher for women (7.3 vs 5.9, P = 0.009). Self-esteem state was high (2.7 ± 0.6 for a maximal value of 3) for the whole cohort without sex differences. A higher difference in the global phenotypic facial acromegaly features score from baseline and post-diagnosis was associated with a lower value on QoL mostly in women (14.38 95% CI 5.25 to 23.52; P-value = 0.005), with less effect in men (6.31 95% CI 0.61 to 13.22; Pvalue = 0.070). Conclusion: In controlled acromegaly, QoL is relatively preserved in both genders, although men have higher general and physical domain scores and lower anxiety status. Facial changes intensity negatively impacted QoL mostly in women.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors

  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Valassi, Elena|||0000-0002-3864-0105
  • Serra, Guillermo
  • Salinas, Isabel
  • Xifra, Gemma
  • Casano-Sancho, Paula
  • Carrato, Cristina|||0000-0002-1953-8287
  • Biagetti, Betina|||0000-0002-8837-4343
  • Sesmilo, Gemma|||0000-0001-5022-1344
  • Marcos-Ruiz, Jennifer
  • Rodriguez-Lloveras, Helena|||0000-0002-6669-3087
  • Rueda-Pujol, Anna|||0000-0002-6671-3180
  • Aulinas, Anna|||0000-0002-1205-7114
  • Blanco, Alberto
  • Hostalot, Cristina|||0000-0002-1935-0524
  • Simó-Servat, Andreu|||0000-0002-1092-1327
  • Muñoz, Fernando
  • Rico, Marta
  • Ibáñez-Domínguez, Javier
  • Cordero Asanza, Esteban|||0000-0003-0464-3014
  • Webb, S. M.|||0000-0001-7052-6436
  • Jordà, Mireia|||0000-0003-3709-1850
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Different medical therapies have been developed for pituitary adenomas. However, Non-Functioning Pituitary Neuroendocrine Tumors (NF-PitNET) have shown little response to them. Furthermore, epithelial-mesenchymal transition (EMT) has been linked to resistance to medical treatment in a significant number of tumors, including pituitary adenomas. We aimed to evaluate the expression of EMT-related markers in 72 NF-PitNET and 16 non-tumoral pituitaries. To further explore the potential usefulness of medical treatment for NF-PitNET we assessed the expression of somatostatin receptors and dopamine-associated genes. We found that SNAI1, SNAI2, Vimentin, KLK10, PEBP1, Ki-67 and SSTR2 were associated with invasive NF-PitNET. Furthermore, we found that the EMT phenomenon was more common in NF-PitNET than in GH-secreting pituitary tumors. Interestingly, PEBP1 was overexpressed in recurrent NF-PitNET, and could predict growth recurrence with 100% sensitivity but only 43% specificity. In parallel with previously reported studies, SSTR3 is highly expressed in our NF-PitNET cohort. However, SSTR3 expression is highly heterogeneous among the different histological variants of NF-PitNET with very low levels in silent corticotroph adenomas. NF-PitNET showed an enhanced EMT phenomenon. SSTR3 targeting could be a good therapeutic candidate in NF-PitNET except for silent corticotroph adenomas, which express very low levels of this receptor. In addition, PEBP1 could be an informative biomarker of tumor regrowth, useful for predictive medicine in NF-PitNET.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

  • Ruiz-Janer, Sabina|||0000-0002-8073-9504
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Biagetti, Betina|||0000-0002-8837-4343
  • Venegas, Eva
  • Cámara, Rosa|||0000-0002-3289-3400
  • García Centeno, Rogelio
  • Gálvez, María-Angeles
  • Picó Alfonso, Antonio M.|||0000-0002-7549-7563
  • Maraver, Silvia
  • González, Inmaculada
  • Abellán-Galiana, Pablo|||0000-0003-1221-3946
  • Trincado, Pablo
  • Herrera, Mayte T.
  • Olvera, Pilar
  • Xifra, Gemma
  • Bernabeu Morón, Ignacio|||0000-0001-8421-7394
  • Serra-Soler, Guillermo
  • Azriel, Sharona
  • García, Lourdes
  • Carvalho, Davide|||0000-0002-3156-3741
  • Jordà, Mireia|||0000-0003-3709-1850
  • Valassi, Elena|||0000-0002-3864-0105
  • Puig, Josep|||0000-0003-2791-6599
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Objective: Hyperintensity signal in T2-weighted magnetic resonance imaging (MRI) has been related to better therapeutic response during pasireotide treatment in acromegaly. The aim of the study was to evaluate T2 MRI signal intensity and its relation with pasireotide therapeutic effectiveness in real-life clinical practice. Design, Patients and Measurements: Retrospective multicentre study including acromegaly patients treated with pasireotide. Adenoma T2-weighted MRI signal at diagnosis was qualitatively classified as iso-hyperintense or hypointense. Insulin-like growth factor (IGF-I), growth hormone (GH) and tumour volume reduction were assessed after 6 and 12 months of treatment and its effectiveness evaluated according to baseline MRI signal. Hormonal response was considered 'complete' when normalization of IGF-I levels was achieved. Significant tumour shrinkage was defined as a volume reduction of ≥25% from baseline. Results: Eighty-one patients were included (48% women, 50 ± 1.5 years); 93% had previously received somatostatin receptor ligands (SRLs) treatment. MRI signal was hypointense in 25 (31%) and hyperintense in 56 (69%) cases. At 12 months of follow-up, 42/73 cases (58%) showed normalization of IGF-I and 37% both GH and IGF-I. MRI signal intensity was not associated with hormonal control. 19/51 cases (37%) presented a significant tumour volume shrinkage, 16 (41%) from the hyperintense group and 3 (25%) from the hypointense. Conclusions: T2-signal hyperintensity was more frequently observed in pasireotide treated patients. Almost 60% of SRLs resistant patients showed a complete normalization of IGF-I after 1 year of pasireotide treatment, regardless of the MRI signal. There was also no difference in the percentage tumour shrinkage over basal residual volume between the two groups.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Valassi, Elena|||0000-0002-3864-0105
  • Hernández García, Marta|||0000-0003-1237-298X
  • Biagetti, Betina|||0000-0002-8837-4343
  • Giménez-Palop, Olga|||0000-0002-4526-6342
  • Martínez, Silvia
  • Carrato, Cristina|||0000-0002-1953-8287
  • Pons, Laura|||0000-0003-0784-4110
  • Villar Taibo, Rocío
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Blanco Carrera, Concepción|||0000-0001-7171-9459
  • Simón, Inmaculada
  • Simó-Servat, Andreu|||0000-0002-1092-1327
  • Xifra, Gemma
  • Vázquez, Federico|||0000-0001-6493-2374
  • Pavón, Isabel
  • García Centeno, Rogelio
  • Zavala, Roxana
  • Hanzu, Felicia A.|||0000-0002-2399-4023
  • Mora, Mireia|||0000-0002-5887-5016
  • Aulinas, Anna|||0000-0002-1205-7114
  • Vilarrasa, Nuria|||0000-0003-3188-1990
  • Librizzi, Soledad
  • Calatayud, María|||0000-0002-6737-7289
  • de Miguel, Paz
  • Álvarez-Escolá, Cristina|||0000-0002-4684-1652
  • Picó Alfonso, Antonio M.|||0000-0002-7549-7563
  • Sampedro Núñez, Miguel Antonio
  • Salinas, Isabel
  • Fajardo-Montañana, Carmen|||0000-0002-0784-0761
  • Cámara, Rosa|||0000-0002-3289-3400
  • Bernabeu Morón, Ignacio|||0000-0001-8421-7394
  • Jordà, Mireia|||0000-0003-3709-1850
  • Webb, S. M.|||0000-0001-7052-6436
  • Marazuela, Mónica|||0000-0003-1158-9618
  • Puig Domingo, Manuel|||0000-0002-6744-7195
We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2). A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was ≥3SDS, were considered non-responders. The 2 hours GH value (GH) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively. In all, 30 patients were responders and 17 were non-responders. GH was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 ± 4.2 vs 3.3 ± 2.1; p=0.01). The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.